Today, Nurosene Health Inc. ( $MEND $MEND.c $MNNDF ) released preliminary findings that support the innovation of and will enable increased efficiency in the development of anti-aging therapeutics!
$MEND utilized age-related data set derived from skin samples to create proprietary data and self-generated insights
$MEND's NetraAI technology derived novel biological mechanisms at play in aging and successfully self-generated hypotheses from the proprietary data sets.
This is quite notable as NetraAI demonstrated it can transform data into powerful insights on how to improve clinical trials and create novel drugs. The technology combines AI, biology, and chemistry to develop predictive models with machine learning
Plus, the significant interest in NetraAI technology will continue to accelerate its path towards novel therapeutics, will help accelerate clinical trials and build Nurosene's IP portfolio.
https://ca.finance.yahoo.com/news/nurosene-releases-preliminary-findings-support-143000347.html